Spravato becomes first FDA-approved standalone depression treatment
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson’s nasal spray, Spravato, as a standalone treatment for adults with major depressive disorder (MDD) that is resistant to conventional therapies. This marks a significant development in the treatment of depression,...